ES2676023T3 - Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso - Google Patents

Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso Download PDF

Info

Publication number
ES2676023T3
ES2676023T3 ES14729996T ES14729996T ES2676023T3 ES 2676023 T3 ES2676023 T3 ES 2676023T3 ES 14729996 T ES14729996 T ES 14729996T ES 14729996 T ES14729996 T ES 14729996T ES 2676023 T3 ES2676023 T3 ES 2676023T3
Authority
ES
Spain
Prior art keywords
region
polypeptides
methods
fusion proteins
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14729996T
Other languages
English (en)
Inventor
Justin Scheer
Wenjun Ouyang
Eric Gary Stefanich
Richard Vandlen
Philip E. HAAS
Ganesh A. Kolumam
Xiaoting WANG
Jed ROSS
Nicholas Van Bruggen
Wyne P. LEE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2676023T3 publication Critical patent/ES2676023T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una proteina de fusion de IL-22 Fc que se une con el receptor de IL-22, comprendiendo dicha proteina de fusion de IL-22 Fc un polipeptido de IL-22 ligado a una region Fc por un enlazador, en donde la region Fc comprende una region de bisagra, un dominio CH2 de IgG y un dominio CH3 de IgG, en donde la proteina de fusion de IL-22 Fc comprende una secuencia de aminoacidos que tiene al menos un 95 % de identidad de secuencia con la secuencia de aminoacidos seleccionada del grupo que consiste en la SEQ ID NO: 8 y la SEQ ID NO: 10, en donde el resto N297 se cambia a Gly o Ala y en donde la region Fc no esta glucosilada.
ES14729996T 2013-03-15 2014-03-14 Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso Active ES2676023T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361801144P 2013-03-15 2013-03-15
US201361800795P 2013-03-15 2013-03-15
US201361800148P 2013-03-15 2013-03-15
US201361821062P 2013-05-08 2013-05-08
US201361860176P 2013-07-30 2013-07-30
PCT/US2014/029652 WO2014145016A2 (en) 2013-03-15 2014-03-14 Il-22 polypeptides and il-22 fc fusion proteins and methods of use

Publications (1)

Publication Number Publication Date
ES2676023T3 true ES2676023T3 (es) 2018-07-16

Family

ID=50942310

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14729996T Active ES2676023T3 (es) 2013-03-15 2014-03-14 Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso

Country Status (29)

Country Link
US (12) US10160793B2 (es)
EP (2) EP3385277A1 (es)
JP (3) JP6456356B2 (es)
KR (1) KR102426481B1 (es)
CN (1) CN105143252A (es)
AU (3) AU2014233494B2 (es)
BR (1) BR112015023140A8 (es)
CA (1) CA2903587C (es)
CL (1) CL2015002654A1 (es)
DK (1) DK2970422T3 (es)
EA (1) EA035645B1 (es)
ES (1) ES2676023T3 (es)
HK (1) HK1218424A1 (es)
HR (1) HRP20181090T1 (es)
HU (1) HUE039291T2 (es)
LT (1) LT2970422T (es)
MX (2) MX368005B (es)
PE (2) PE20151673A1 (es)
PH (2) PH12015502125B1 (es)
PL (1) PL2970422T3 (es)
PT (1) PT2970422T (es)
RS (1) RS57393B1 (es)
SG (2) SG10201808523RA (es)
SI (1) SI2970422T1 (es)
TR (1) TR201809571T4 (es)
TW (2) TWI772250B (es)
UA (1) UA118843C2 (es)
WO (1) WO2014145016A2 (es)
ZA (1) ZA201506297B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP2950807B1 (en) 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
PE20151673A1 (es) 2013-03-15 2015-11-27 Genentech Inc POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
CN104623639A (zh) * 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
ES2739129T5 (es) 2013-11-07 2024-04-02 Memorial Sloan Kettering Cancer Center IL-22 para uso en el tratamiento de la enfermedad gastrointestinal del injerto contra el huesped
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
TN2016000578A1 (en) 2014-07-30 2018-04-04 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
EP3212226B1 (en) 2014-10-31 2020-03-18 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
WO2016108130A1 (en) * 2014-12-30 2016-07-07 Sun Pharmaceutical Industries Limited Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds
MX2017012966A (es) 2015-04-10 2018-06-06 Amgen Inc Muteinas de interleuquina 2 para la expansion de celulas t regulatorias.
CN106317225A (zh) * 2015-06-28 2017-01-11 复旦大学 具有靶向性长效白细胞介素22融合蛋白及其制备方法和用途
CR20180087A (es) 2015-07-16 2018-05-14 Philogen Spa Inmunoconjugados de il22
KR20250008141A (ko) * 2015-08-07 2025-01-14 이미지냅 인코포레이티드 분자를 표적화하기 위한 항원 결합 구조체
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
WO2017172260A1 (en) 2016-03-31 2017-10-05 Ngm Bioparmaceuticals, Inc. Binding proteins and methods of use thereof
ES2930351T3 (es) 2016-04-15 2022-12-09 Evive Biotechnology Shanghai Ltd Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante
WO2017191817A1 (ja) * 2016-05-02 2017-11-09 味の素株式会社 アジド基含有Ｆｃタンパク質
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
ES2874974T3 (es) 2016-05-11 2021-11-05 Cytiva Bioprocess R & D Ab Matriz de separación
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
ES2909833T3 (es) 2016-05-11 2022-05-10 Cytiva Bioprocess R & D Ab Método de limpieza y/o desinfección de una matriz de separación
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
KR102050463B1 (ko) 2016-08-10 2019-11-29 아주대학교산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
CN108239151B (zh) * 2016-12-23 2020-07-03 海门晟斯生物制药有限公司 重组单链人FVIII-Fc融合蛋白及其应用
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
BR112019017853A2 (pt) 2017-02-28 2021-04-27 Vib Vzw Meios e métodos para liberação oral de proteína
CN108948207B (zh) * 2017-05-22 2020-11-13 杭州博虎生物科技有限公司 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用
LT3743088T (lt) * 2018-01-26 2022-12-27 F. Hoffmann-La Roche Ag Il-22 fc kompozicijos ir jų naudojimo būdai
SG11202006259SA (en) 2018-01-26 2020-08-28 Genentech Inc Il-22 fc fusion proteins and methods of use
JP2021514354A (ja) * 2018-02-21 2021-06-10 ジェネンテック， インコーポレイテッド ＩＬ−２２Ｆｃ融合タンパク質による治療のための投与
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US11834472B2 (en) 2018-06-05 2023-12-05 Bioatla, Inc. Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN108918571B (zh) * 2018-06-15 2021-02-02 山西大学 代谢标志物在制备肾病综合征病变进程诊断鉴别试剂中的应用
AU2019318209B2 (en) * 2018-08-10 2025-09-25 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
WO2020051498A1 (en) 2018-09-06 2020-03-12 Cidara Therapeutics, Inc. Compositions and methods for the treatment of viral infections
EP3849605A4 (en) 2018-09-10 2022-06-15 Cold Spring Harbor Laboratory METHODS OF TREATMENT OF PANCREATITIS
CA3117212A1 (en) * 2018-10-23 2020-04-30 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins
EA202191280A1 (ru) * 2018-11-07 2021-12-27 Эпплайд Молекьюлар Транспорт Инк. Конструкции для доставки для трансцитоза и связанные способы
JP7487193B2 (ja) 2018-11-07 2024-05-20 アプライド モレキュラー トランスポート インコーポレイテッド 異種ペイロードの経口送達のためのコリックス由来担体
WO2020112773A1 (en) * 2018-11-27 2020-06-04 The General Hospital Corporation Targeting intraepithelial lymphocytes for treatment of metabolic syndrome
CN114206373A (zh) * 2019-07-26 2022-03-18 豪夫迈·罗氏有限公司 用于以IL-22 Fc融合蛋白预防或治疗移植物抗宿主病(GVHD)的给药
UY38836A (es) 2019-08-13 2021-02-26 Amgen Inc Muteínas de interleucina-2 para la expansión de células t reguladoras
CN114599665A (zh) 2019-08-16 2022-06-07 应用分子转运公司 组合物、制剂及白细胞介素产生和纯化
AU2020342512A1 (en) * 2019-09-03 2022-03-31 Amgen Inc. IL-22 oral, intra-rectal, or other gut-related compositions and methods of use thereof
TWI861205B (zh) 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法
WO2021062012A1 (en) * 2019-09-25 2021-04-01 Emory University Use of klk10 and engineered derivatizations thereof
CN112618698B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白的注射制剂
EP3819307A1 (en) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
WO2021164744A1 (en) 2020-02-19 2021-08-26 Evive Biotechnology (Shanghai) Ltd Methods for treating graft versus host disease
JP2023518814A (ja) 2020-03-23 2023-05-08 ジェネンテック， インコーポレイテッド Ｃｏｖｉｄ－１９肺炎における、ｉｌ－６アンタゴニストに対する応答を予測するためのバイオマーカー
WO2021207662A1 (en) * 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
MX2022012822A (es) * 2020-04-17 2023-01-04 Univ Leland Stanford Junior Polipeptidos modificados de interleucina-22 y usos de los mismos.
PE20230983A1 (es) 2020-08-07 2023-06-21 Genentech Inc Proteinas de fusion del ligando para flt3 y metodos de uso
CN112007146A (zh) * 2020-09-03 2020-12-01 上海市儿童医院 Il-22在治疗和/或预防脓毒症诱发的肝脏损伤的药物中的用途
EP4213877A1 (en) 2020-09-17 2023-07-26 Genentech, Inc. Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
BR112023009875A2 (pt) 2020-11-23 2024-02-06 Genentech Inc Métodos para tratar um indivíduo com uma infecção por sars-cov-2, para reduzir a ligação de sars-cov-2 a uma célula, para diminuir a infecção por sars-cov-2 e para identificar um modulador, métodos de profilaxia, moduladores isolados, usos e antagonistas
WO2022192419A2 (en) 2021-03-09 2022-09-15 Massachusetts Institute Of Technology Methods of treating inflammatory bowel disease (ibd) with anti- tnf-blockade
WO2022238503A1 (en) * 2021-05-11 2022-11-17 Cytoki Pharma Aps Therapeutic derivatives of interleukin-22
AU2023367177A1 (en) * 2022-10-26 2025-04-17 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Engineered bacterium and uses thereof for treating cancer
KR102923942B1 (ko) * 2022-11-10 2026-02-06 (주)네오크레마 Il-22를 포함하는 융합 단백질 및 이의 용도

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
WO1984003506A1 (en) 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4717717A (en) 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5705485A (en) 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
KR0154872B1 (ko) 1987-12-21 1998-10-15 로버트 에이. 아미테이지 발아하는 식물종자의 아크로박테리움 매개된 형질전환
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP0558671B1 (en) 1990-11-21 1999-01-27 Iterex Pharmaceuticals Ltd. Partnership Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6143498A (en) 1997-05-14 2000-11-07 Human Genome Sciences, Inc. Antimicrobial peptide
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO2002016611A2 (en) 2000-08-24 2002-02-28 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP1066045B1 (en) 1997-10-08 2004-12-29 Theragem, Inc. Mammalian-derived peptides for the treatment of microbial infection
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
CA2329274A1 (en) 1998-05-29 1999-12-02 Steven M. Ruben Interleukin-21
US20010023070A1 (en) 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
DE69936212T2 (de) 1998-09-04 2008-01-24 Scios Inc., Sunnyvale Hydrogelzusammensetzungen mit kontrollierter Freigabe für die Verabreichung von Wachstumsfaktoren
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
BR9914777A (pt) 1998-10-26 2001-07-03 Ludwig Inst Cancer Res Moléculas isoladas de ácido nucléico que codificam os fatores induzìveis por células t (tifs), as proteìnas codificadas e os usos das mesmas
JP2002533726A (ja) 1998-12-28 2002-10-08 サネシス ファーマシューティカルス インコーポレイテッド 結合のための小有機分子リガンドの同定
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
ATE377077T1 (de) 1999-04-28 2007-11-15 Genetics Inst Llc Humane gil-19/ae289 proteine und dafür kodierende polynukleotide
WO2000073457A1 (en) 1999-05-27 2000-12-07 Schering-Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
AU3774300A (en) 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US7226591B2 (en) 2000-05-22 2007-06-05 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
JP2003524415A (ja) 1999-12-23 2003-08-19 ザイモジェネティクス，インコーポレイティド サイトカインｚｃｙｔｏ１８
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
GB0024442D0 (en) 2000-10-05 2000-11-22 Isis Innovation Genetic factors affecting the outcome of viral infections
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2438238A1 (en) 2001-02-23 2002-09-06 Genetics Institute, Llc. Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
US7638604B2 (en) 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
CA2439961A1 (en) 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2003034984A2 (en) 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
FR2833011B1 (fr) 2001-12-04 2004-10-29 Univ Claude Bernard Lyon Nouvelle proteine a activite inhibitrice de l'il-6
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1546358A4 (en) 2002-03-22 2006-06-07 Zymogenetics Inc ANTI-IL-TIF ANTIBODIES AND METHOD FOR USE ON INFLAMMATION
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
US20030235561A1 (en) 2002-06-25 2003-12-25 Cell Based Delivery Inc. Vascularized organized tissues and uses thereof
AU2003256299A1 (en) 2002-07-01 2004-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
US20040176293A1 (en) 2002-12-18 2004-09-09 Wyeth Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
RU2337107C2 (ru) 2003-05-02 2008-10-27 Ксенкор, Инк. ОПТИМИЗИРОВАННЫЕ Fc-ВАРИАНТЫ, ИМЕЮЩИЕ ИЗМЕНЕННОЕ СВЯЗЫВАНИЕ С FcγR, И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
RU2006101702A (ru) 2003-06-23 2006-09-10 Дженетикс Инститьют, Ллс (Us) Антитела против интерлейкина-22 и их применения
WO2005012492A2 (en) 2003-08-01 2005-02-10 Stratatech Corporation Human skin equivalents expressing exogenous polypeptides
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
ATE493142T1 (de) 2003-11-05 2011-01-15 Inst Rech Developpement Ird Il-22 zur verhinderung von infektionskrankheiten
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
PT1699822E (pt) 2003-12-30 2008-07-30 Merck Patent Gmbh Proteínas de fusão de il-7
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
US20050277593A1 (en) 2004-05-24 2005-12-15 Washington University Therapeutic uses of Reg protein
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN100515491C (zh) 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
AU2006259408A1 (en) 2005-06-17 2006-12-28 Genentech, Inc. Use of VEGF for wound healing
RU2302460C1 (ru) 2005-11-02 2007-07-10 Институт цитологии и генетики Сибирского отделения Российской академии наук (СО РАН) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBi101-IL18, КОДИРУЮЩАЯ СИНТЕЗ ИНТЕРЛЕЙКИНА-18 ЧЕЛОВЕКА В ТРАНСГЕННЫХ РАСТЕНИЯХ
EP1962584A2 (en) 2005-11-21 2008-09-03 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
AU2006342792A1 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
CN101472611A (zh) 2006-06-19 2009-07-01 惠氏公司 调节il-22和il-17的方法
TW200827441A (en) * 2006-08-21 2008-07-01 Nat University Corp Of Kobe University Method for preparing fusion protein
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20080267910A1 (en) 2007-03-09 2008-10-30 Wu Paul W Rat, rabbit, and cynomolgus monkey IL-21 and IL-22 nucleotide and polypeptide sequences
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
WO2009026524A1 (en) 2007-08-22 2009-02-26 Baylor College Of Medicine Delipidation of hdl using serum opacity factor to prevent atherosclerosis
CN101225110B (zh) 2007-10-23 2010-10-20 中国人民解放军军事医学科学院基础医学研究所 人白细胞介素-22突变体及其构建方法和应用
RU2503460C2 (ru) 2007-11-07 2014-01-10 Дженентек Инк. Применение противомикробного полипептида для лечения микробных нарушений
WO2009117640A2 (en) 2008-03-21 2009-09-24 Wyeth Antibodies against interleukin-10 like cytokines and uses therefor
CN102171343B (zh) * 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
WO2010081112A1 (en) 2009-01-12 2010-07-15 Yu Liang Huang Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22
BRPI1006998A2 (pt) * 2009-01-23 2015-08-25 Biogen Idec Inc Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso
WO2010124018A1 (en) 2009-04-21 2010-10-28 Amgen Inc. FRAGMENTATION RESISTANT IgG1 Fc-CONJUGATES
JP5523771B2 (ja) 2009-09-02 2014-06-18 三菱農機株式会社 移植機
GB0916124D0 (en) 2009-09-15 2009-10-28 Univ Cardiff Method and kit for the classification and prognosis of wounds
WO2011087986A1 (en) * 2010-01-13 2011-07-21 Amgen Inc. Il-22-fc and hepcidin activity
CA2796633C (en) 2010-04-23 2020-10-27 Genentech, Inc. Production of heteromultimeric proteins
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
EP2668207A4 (en) 2011-01-24 2015-06-10 Univ Singapore MANNOSE-CAPTURED LIPOARABINOMANANE ANTIGEN-BINDING PROTEINS OBTAINED FROM ILLNESSIFYING MYCOBACTERIES
HRP20240230T1 (hr) 2011-10-11 2024-04-26 F. Hoffmann - La Roche Ag Poboljšani sklop bispecifičnih protutijela
CN103182072B (zh) 2011-12-27 2017-05-03 健能隆医药技术（上海）有限公司 白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途
JP5668708B2 (ja) 2012-02-14 2015-02-12 住友電気工業株式会社 光プローブ
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
PE20151673A1 (es) 2013-03-15 2015-11-27 Genentech Inc POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO

Also Published As

Publication number Publication date
JP7245021B2 (ja) 2023-03-23
ZA201506297B (en) 2018-11-28
LT2970422T (lt) 2018-06-25
AU2020205284A1 (en) 2020-08-06
PE20211272A1 (es) 2021-07-19
US11155591B2 (en) 2021-10-26
US20190177387A1 (en) 2019-06-13
SG10201808523RA (en) 2018-11-29
MX2019010846A (es) 2019-10-30
TW202214675A (zh) 2022-04-16
CL2015002654A1 (es) 2016-07-15
US20230063741A1 (en) 2023-03-02
HUE039291T2 (hu) 2018-12-28
US20140314711A1 (en) 2014-10-23
WO2014145016A3 (en) 2015-03-05
UA118843C2 (uk) 2019-03-25
TWI772250B (zh) 2022-08-01
PH12020550205A1 (en) 2021-09-01
CA2903587C (en) 2021-09-28
NZ751499A (en) 2021-07-30
US10544198B2 (en) 2020-01-28
AU2018223004A1 (en) 2018-09-20
JP2019030308A (ja) 2019-02-28
US20190233491A1 (en) 2019-08-01
KR102426481B1 (ko) 2022-07-27
EP2970422B1 (en) 2018-04-18
US11332507B2 (en) 2022-05-17
HK1218424A1 (zh) 2017-02-17
DK2970422T3 (en) 2018-07-16
US20180362608A1 (en) 2018-12-20
EP2970422A2 (en) 2016-01-20
CA2903587A1 (en) 2014-09-18
US20190177390A1 (en) 2019-06-13
US11130791B2 (en) 2021-09-28
US20190177389A1 (en) 2019-06-13
TW201524995A (zh) 2015-07-01
US20190177386A1 (en) 2019-06-13
TR201809571T4 (tr) 2018-07-23
AU2014233494A1 (en) 2015-09-03
MX368005B (es) 2019-09-13
PE20151673A1 (es) 2015-11-27
PH12015502125A1 (en) 2016-01-25
BR112015023140A2 (pt) 2017-11-21
RS57393B1 (sr) 2018-09-28
BR112015023140A8 (pt) 2018-01-23
US10160793B2 (en) 2018-12-25
HRP20181090T1 (hr) 2018-09-07
CN105143252A (zh) 2015-12-09
SG11201507429TA (en) 2015-10-29
US20170008942A1 (en) 2017-01-12
SI2970422T1 (en) 2018-07-31
JP6456356B2 (ja) 2019-01-23
KR20150128944A (ko) 2015-11-18
US20170320926A1 (en) 2017-11-09
MX2015011146A (es) 2016-03-08
AU2018223004B2 (en) 2020-04-16
PL2970422T3 (pl) 2018-09-28
US10584155B2 (en) 2020-03-10
PT2970422T (pt) 2018-07-06
AU2014233494B2 (en) 2018-10-04
US11136365B2 (en) 2021-10-05
US20190177388A1 (en) 2019-06-13
PH12015502125B1 (en) 2022-02-11
EA035645B1 (ru) 2020-07-21
WO2014145016A2 (en) 2014-09-18
NZ711095A (en) 2021-06-25
JP2022046520A (ja) 2022-03-23
US9815880B2 (en) 2017-11-14
US20170088596A1 (en) 2017-03-30
EA201591515A1 (ru) 2016-03-31
EP3385277A1 (en) 2018-10-10
US10087227B2 (en) 2018-10-02
JP2016522795A (ja) 2016-08-04

Similar Documents

Publication Publication Date Title
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
EA201591700A1 (ru) Гибридные белки апелина и их применение
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
BR112016016411A2 (pt) VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS
FI3677591T3 (fi) Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b
ES2676499T3 (es) Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
BR112016016416A2 (pt) VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS
PL397167A1 (pl) Przeciwnowotworowe bialko fuzyjne
AR095115A1 (es) Anticuerpos que comprenden dominios constantes quiméricos
MX2018000697A (es) Peptidos anti-inflamatorios y usos de los mismos.
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
PE20191033A1 (es) PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
MX380658B (es) Variantes de region fc con union mejorada de la proteina a.
AR094149A1 (es) Proteinas multifuncion que comprenden chm de clase i multivalente unido mediante disulfuro
MX2015000397A (es) Complejo del factor viii con xten y proteina del factor von willebrand, y sus usos.
CY1119149T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
AR093641A1 (es) Eliminacion de celulas de cancer por celulas t citotoxicas circulantes especificas de virus utilizando proteinas multifuncion que comprenden cmh de clase i con diana en celulas de cancer
EA201500741A1 (ru) ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
MX389878B (es) Proteinas quimericas de factor viii y usos de estas.
UA117493C2 (uk) Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання
CY1116646T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
MX387560B (es) Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
EA201491277A1 (ru) Противораковый слитый белок